{"disease":{"id":"locally-recurrent-colorectal-cancer","name":"locally recurrent colorectal cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06114420","title":"Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06307548","title":"Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer","phase":"PHASE1, PHASE2","overall_status":"SUSPENDED","enrollment_count":21,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT06881537","title":"CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}